PepGen
Chris joined OSI in December 2019. He is a seasoned biotech entrepreneur with over has 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies and their transition to mid-stage clinical development organisations. He has extensive international transactional experience including fund raising, licensing and M&A activity. Chris was formerly a Partner at Syncona and was also the founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (acquired by Galapagos) and Pulmagen Therapeutics. Chris has a PhD from UMIST and carried out post-doctoral research at MIT.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
PepGen
2 followers
Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.